Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.
Related Videos In Sarcoma
Brian Van Tine, ASCO20: Summary of the Phase 1 SPEARHEAD-1 Trial in Sarcoma
Brian Van Tine, Washington University in St. Louis, discusses the data presented at ASCO20 from the Phase I SPEARHEAD-1 study of T-cell receptor therapy ADP-A2M4 in patients with solid tumors previously treated with chemotherapy. Questions 1. What are the major limitations and unmet needs of T cell therapy, especially with the current available CAR-Ts? (0:06) […]
Brian Van Tine, ESMO 2019 – Pazopanib in soft tissue sarcomas
Brain Van Tine (Washington University in St Louis) joins us to discuss the results of the phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy (NCT02300545). Questions 1. What are the limitations of standard first-line chemotherapy in the treatment of soft […]
Alona Zer, ASCO 2019 – Phase II study of nivolumab and ipilimumab in CKS
At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671). Questions 1. Could you tell us a little about Classic Kaposi Sarcoma (CKS) and its prognosis? (0:04) 2. What is the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!